Dianthus therapeutics appoints simon read, ph.d., to board of directors

Dr. read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry previously served as ceo and founder of mariana oncology until its acquisition by novartis in 2024 and cso of ra pharma until its acquisition by ucb in 2020 new york and waltham, mass., may 22, 2025 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of simon read, ph.d.
DNTH Ratings Summary
DNTH Quant Ranking